Market Place
Sourcing Support
HiberCell Receives FDA Fast Track for HC-7366 in AML Treatment
23 Oct 2024 //
GLOBENEWSWIRE
HiberCell: First Patient Dosed In AML Combination Trial Of HC-7366
28 May 2024 //
GLOBENEWSWIRE
HiberCell: First Patient Dosed In Merck Combo Trial For ccRCC
01 May 2024 //
GLOBENEWSWIRE
HiberCell Announces Publication & Presentations for its GCN2 Activator, HC-7366
05 Apr 2024 //
GLOBENEWSWIRE
HiberCell Announces Presentation at ASH, Highlighting Data for HC-7366
15 Dec 2023 //
GLOBENEWSWIRE
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366
05 Dec 2023 //
GLOBENEWSWIRE
HiberCell Announces Completion and Interim Results of Phase 1 Study of HC-5404
27 Nov 2023 //
GLOBENEWSWIRE
HiberCell Doses First Patient in Phase 1b Study Exploring CDX-1140
22 May 2023 //
GLOBENEWSWIRE
HiberCell to Present Data on Novel GCN2 Activator and PERK Inhibitor Programs
24 Mar 2023 //
GLOBENEWSWIRE
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in AML
22 Feb 2023 //
GLOBENEWSWIRE
HiberCell to Present Data from Novel GCN2 Activator at SITC
02 Nov 2022 //
GLOBENEWSWIRE
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366
24 May 2022 //
GLOBENEWSWIRE
HiberCell Announces First Patients Dosed in PII Clinical Trial of Odetiglucan
28 Apr 2022 //
GLOBENEWSWIRE
HiberCell to Present Clinical Appln of Odetiglucan & Beta-Glucan in Cancer
03 Mar 2022 //
GLOBENEWSWIRE
HiberCell commences Phase I solid tumour trial of GCN2 modulator
25 Feb 2022 //
CLINICALTRIALSARENA
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366
24 Feb 2022 //
GLOBENEWSWIRE
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan
14 Dec 2021 //
GLOBENEWSWIRE
HiberCell to Present Clinical Use of Odetiglucan & Beta-Glucan in Cancer therapy
09 Dec 2021 //
PRNEWSWIRE
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab Ongoing Ph2
07 Dec 2021 //
GLOBENEWSWIRE
HiberCell Receives Fast Track Designation for PERK Inhibitor HC-5404-FU
08 Sep 2021 //
GLOBENEWSWIRE
HiberCell leverages soft skill tools in buyout
16 Aug 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.